SuperGen Company

SuperGen operates a pharmaceutical company dedicated to the research and discovery of oncological drug therapy.
SuperGen, Inc., a pharmaceutical company, engages in the discovery, development, and commercialization of therapies to treat patients with cancer. Products in Development MP-470DNA Repair Suppressor: MP-470 is a multi-targeted Tyrosine Kinase Inhibitor that is specific for mutant forms of c-kit, PDGFRa, and FLT3. These protein kinase targets are involved in the growth and proliferation of cancer cells. MP-470 is also a suppressor of Rad51, a DNA repair protein which is involved in resistance to various chemotherapy agents and radiation.

Investors

Technology: Preventive Medicine
Industry: Precision Medicine
Headquarters: Dublin
Founded Date: 1991
Employees Number: 51-100
Funding Status: undisclosed

Visit Website
Register and Claim Ownership